At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06118 AUSTAR
Market Closed 11-13 15:18:07
0.535
+0.015
+2.88%
High0.540Low0.520Vol13.00K
Open0.520D1 Closing0.520Amplitude3.85%
Mkt Cap274.46MTradable Cap274.23MTotal Shares513.00M
T/O6.80KT/O Rate0.00%Tradable Shares512.58M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
AUSTAR Reports Stable Capital Structure in October 2026 Monthly Return
Bulletin Express  ·  11-02
AUSTAR Reports Stable Capital Structure in October 2026 Monthly Return
Austar Lifesciences: No Share Capital Changes Recorded for September 2026; Public Float Remains Above 25% Threshold
Bulletin Express  ·  10-02
Austar Lifesciences: No Share Capital Changes Recorded for September 2026; Public Float Remains Above 25% Threshold
Austar Lifesciences FY26 Interim Profit Attributable to Owners Drops 66.15% to RMB 8.46 Million; Revenue Rises 12.5% to RMB 744.48 Million
Reuters  ·  09-11
Austar Lifesciences FY26 Interim Profit Attributable to Owners Drops 66.15% to RMB 8.46 Million; Revenue Rises 12.5% to RMB 744.48 Million
Sweden's Cereno Scientific Q2 Net Loss Widens, Hurt by Clinical Development Costs
Reuters  ·  08-26
Sweden's Cereno Scientific Q2 Net Loss Widens, Hurt by Clinical Development Costs
China's Clover Biopharma H1 Revenue Drops Sharply, Flags Going-Concern Doubt
Reuters  ·  08-26
China's Clover Biopharma H1 Revenue Drops Sharply, Flags Going-Concern Doubt
AUSTAR H1 2026: Revenue Rises 12.5% to RMB 744.48 Million, Net Profit Slumps 66% on Margin Compression
Bulletin Express  ·  08-25
AUSTAR H1 2026: Revenue Rises 12.5% to RMB 744.48 Million, Net Profit Slumps 66% on Margin Compression
AUSTAR Posts Interim Results: Net Profit Attributable to Shareholders Drops 66.15% to RMB 8.463 Million
Stock News  ·  08-25
AUSTAR Posts Interim Results: Net Profit Attributable to Shareholders Drops 66.15% to RMB 8.463 Million
Austar Lifesciences H1 Profit Drops on Higher R&D Spending
Reuters  ·  08-25
Austar Lifesciences H1 Profit Drops on Higher R&D Spending
Austar Lifesciences FY26 Interim Profit Attributable to Owners Drops 66.15% to RMB 8.46 Million; Revenue Rises 12.48% to RMB 744.48 Million
Reuters  ·  08-25
Austar Lifesciences FY26 Interim Profit Attributable to Owners Drops 66.15% to RMB 8.46 Million; Revenue Rises 12.48% to RMB 744.48 Million
Austar Lifesciences H1 Revenue RMB 744.484 Million
THOMSON REUTERS  ·  08-25
Austar Lifesciences H1 Revenue RMB 744.484 Million
AUSTAR Sets 25 August Board Meeting to Approve 1H 2026 Interim Results and Assess Dividend
Bulletin Express  ·  08-13
AUSTAR Sets 25 August Board Meeting to Approve 1H 2026 Interim Results and Assess Dividend
Austar Lifesciences Schedules Board Meeting to Review Interim Results, Dividend Option
Reuters  ·  08-13
Austar Lifesciences Schedules Board Meeting to Review Interim Results, Dividend Option
AUSTAR Posts Zero Share Capital Changes in July 2026, Confirms Public Float Compliance
Bulletin Express  ·  08-06
AUSTAR Posts Zero Share Capital Changes in July 2026, Confirms Public Float Compliance
Austar Lifesciences Expects HY Profit Attributable of RMB8 Million-RMB10 Million
Reuters  ·  07-30
Austar Lifesciences Expects HY Profit Attributable of RMB8 Million-RMB10 Million
Austar Lifesciences forecasts 60–68% interim profit decline amid margin pressure and higher promotion costs
Bulletin Express  ·  07-30
Austar Lifesciences forecasts 60–68% interim profit decline amid margin pressure and higher promotion costs
Austar Lifesciences - Expects Hy Result Due to Absence of Rmb11.4 Mln One-off Exchange Gains Recorded in H1 2025
THOMSON REUTERS  ·  07-30
Austar Lifesciences - Expects Hy Result Due to Absence of Rmb11.4 Mln One-off Exchange Gains Recorded in H1 2025
Austar Lifesciences - Expects H1 2026 Profit Attributable to Owners of RMB8 Mln-RMB10 Mln
THOMSON REUTERS  ·  07-30
Austar Lifesciences - Expects H1 2026 Profit Attributable to Owners of RMB8 Mln-RMB10 Mln
Austar Lifesciences Sees H1 Profit Attributable to Owners at RMB 8 million-RMB 10 Million
Reuters  ·  07-30
Austar Lifesciences Sees H1 Profit Attributable to Owners at RMB 8 million-RMB 10 Million
AUSTAR maintains 512.58 million issued shares in June 2026; public float requirement met
Bulletin Express  ·  07-02
AUSTAR maintains 512.58 million issued shares in June 2026; public float requirement met
China Harmony Auto Names Leung Oi Kin Independent Non-executive Director as Lau Kwok Fan Steps Down
Reuters  ·  06-30
China Harmony Auto Names Leung Oi Kin Independent Non-executive Director as Lau Kwok Fan Steps Down

Introduction

Company Name.
AUSTAR
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Austar Lifesciences Ltd is a holding company that mainly engaged in providing integrated engineering solutions, and manufacturing and distributing pharmaceutical equipment and consumables. The Company operates six segments: Fluid and Bioprocess Systems segment, Cleanroom and Automation Control and Monitoring Systems segment, Powder and Solid Systems segment, GMP Compliance Services segment, Life Science Consumables segment, and Distribution and Agency of Pharmaceutical Equipment segment. The Company's products include clean utility equipment and systems, bioprocess equipment and systems, powder and solid equipment and systems, pharmaceutical process contamination control products, packaging and closed transport products, biosafety and laboratory animal equipment and consumables, and others.
Issue price:
--